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Abstract
Purpose—The frequency and types of breast symptoms reported by women in the National 
Breast and Cervical Cancer Early Detection Program (NBCCEDP) have never been characterized. 
This study aims to establish the frequency of reported symptoms and the diagnostic outcomes 
associated with reported symptoms.
Methods—We examined the frequency of symptoms reported prior to mammography using 
medical record abstraction data from women in the NBCCEDP. We also calculated adjusted odds 
ratios (aOR) of having an abnormal mammogram, an abnormal clinical breast examination (CBE), 
or a final diagnosis of breast cancer by symptoms, compared to asymptomatic women.
Results—In our sample of women, 10.3% reported at least one symptom. Women with 
symptoms were younger and more likely to be non-Hispanic white. Among those reporting 
symptoms, breast lump (31.7%) and pain or tenderness (49.3%) was most common. A relatively 
low proportion of women with symptoms were diagnosed with in situ (0.9%) or invasive breast 
cancer (4.3%). However, a self-reported breast lump (aOR: 13.7; 95% confidence interval [CI]: 
7.8 – 24.1), inflammation or changes to the skin/nipple (aOR: 27.8; 95% CI: 8.7 – 88.8) and other 
or unspecified symptoms (aOR: 3.4; 95% CI: 2.1 – 7.5) were associated with an increased risk of 
invasive breast cancer.
Conclusions—Although the prevalence of breast cancer among women reporting symptoms is 
relatively low, knowing which symptoms carry the highest breast cancer risk is important to assist 
in appropriate diagnostic workup.
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In 2010, nearly 207,000 incident cases and 41,000 deaths resulted from breast cancer in the 
United States (1). This common cancer is a heterogeneous disease with no single 
characterized cause or presentation. Breast symptoms are commonly reported in primary 
care practice and approximately 75% of diagnostic mammographic examinations are among 
women who present with a breast problem (2–4). Over a 10-year period, 16% of women age 
40–69 will have breast problems (5). Common breast complaints include inflammation, 
lump, pain, and nipple discharge (5, 6). Knowing which breast symptoms carry the highest 
risk for cancer is important in the clinical work-up of symptoms and in communicating to 
patients about their risk (7). Diagnostic mammography is performed in women with self-
reported symptoms, an abnormal clinical breast examination, or an abnormal screening 
mammogram. These radiographic exams are more complex and time-consuming than 
routine screening mammograms and may include additional radiographic views or spot 
compressions.
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is a 
nationwide, comprehensive public health program that provides breast and cervical cancer 
screening and diagnostic services to low-income, uninsured, and under-insured women 21 to 
64 years of age (8). The NBCCEDP also serves a few women over age 64 that do not have 
Medicare coverage. Since its inception, the NBCCEDP has provided services to 4.3 million 
women and provided more than 10.7 million breast and cervical cancer examinations (9). In 
recent years, the NBCCEDP has provided over 300,000 mammograms annually (9). Among 
the women receiving breast exams, 48% are non-Hispanic white, 16% are non-Hispanic 
black, 12% are non-Hispanic other and 25% are Hispanic (9). Though often referred to as a 
screening program, the NBCCEDP enrolls both asymptomatic women for cancer screening 
and symptomatic women for diagnostic services.
Because the NBCCEDP regularly accepts symptomatic women for breast services, and 
because diagnostic mammograms are more involved than screening exams, understanding 
the proportion of symptomatic women entering the NBCCEDP is paramount for its 
administrators (10, 11). Additionally, understanding the types of symptoms reported in 
women enrolled in the NBCCEDP and their clinical outcomes can provide valuable 
information to clinicians responsible for their follow-up and care (12). However, the 
frequency and diagnostic outcomes of self-reported breast symptoms in the NBCCEDP have 
never been fully characterized. Our study aims to estimate the frequency of reported breast 
symptoms in the NBCCEDP, characterize the types of breast symptoms reported, and 
describe diagnostic outcomes by symptom type.
METHODS
Sampling and data collection
The Centers for Disease Control and Prevention (CDC) implements the NBCCEDP through 
cooperative agreements with all 50 states, the District of Columbia, 5 US territories, and 11 
American Indian/Alaska Native tribes and tribal organizations. Each grantee reports to CDC 
a subset of standardized program surveillance and evaluation data known as the minimum 
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data elements (MDEs). CDC uses these data to monitor client demographic and clinical 
outcomes, establish NBCCEDP policies and best practices, assess screening outcomes, and 
respond to informational needs of CDC stakeholders and partners.
To ensure the integrity of the NBCCEDP data, in 2004 CDC initiated an extensive 
evaluation project, the MDE Validation Project (13). MDE data were compared with data in 
medical records from a sample of six states. At the time, the participating states were the 
largest screening volume programs and together contributed to over 32% of the national 
MDE data. Within each state, we used a complex sampling design consisting of a two-stage, 
stratified, random sample to select providers and patient records meant to be representative 
of the national MDE data. The detailed sampling design has been described previously (13). 
Trained medical record abstractors collected data from 5,603 breast and cervical cancer 
screening records. Of these, 2,961 were for women who received a federally funded 
mammogram through the NBCCEDP (representing a weighted sample of 311,582 women in 
the national MDE data). From any record with a mammogram, we captured detailed 
information on the breast symptoms reported by the patient and recorded in the medical 
chart, mammography and clinical breast exam (CBE) results, and final diagnostic outcomes.
Variable definitions
Medical record abstractors trained specifically for this study reviewed the files and recorded 
whether any breast symptoms self-reported by the patient were noted in the medical chart. If 
the presence of symptoms was noted, we grouped them as follows: lump (lump, mass, or 
single nodule); pain or tenderness; thickening or fibrocystic changes (thickening, fibrocystic 
changes or nodules); inflammation or changes to the skin/nipple (redness/inflammation of 
the skin, changes in breast size/shape or skin dimpling or skin/nipple retraction); nipple 
discharge (bloody or other nipple discharge); and other or unspecified (e.g., rash, cysts, 
induration).
Women reported demographic characteristics including age, race and ethnicity, and prior 
screening history at the time of enrollment in the NBCCEDP. Providers reported dates and 
results of CBEs, mammograms, diagnostic procedures, and outcomes. CBE results were 
categorized as normal, abnormal, or unknown. Mammogram results were reported according 
to the Breast Imaging Reporting and Data System (BI-RADS) (14). For modeling the odds 
of abnormal mammogram results, we considered those categorized as a suspicious 
abnormality (BI-RADS 4) or suggestive of malignancy (BI-RADS 5) as abnormal results. 
We also modeled the odds of a final diagnosis of in situ and invasive breast cancers, 
separately as well as a diagnosis of either.
Analysis
All analyses were performed using SAS software version 9.3 (SAS Institute, Inc., Cary, 
North Carolina) (15). We applied appropriate sampling weights and used SAS-callable 
SUDAAN version 11.0.0 (RTI International: Research Triangle Park, North Carolina) to 
correct for the complex sampling design.
We used the Pearson’s Chi-square test of independence to explore differences in the 
prevalence of any self-reported breast symptoms by various patient characteristics and 
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clinical findings. We used logistic regression to estimate the adjusted odds ratios (aORs) and 
95% confidence intervals (CIs) of the following outcomes for women with specific breast 
symptoms compared with those with no breast symptoms: an abnormal CBE; an abnormal 
mammogram; either an abnormal CBE or mammogram; a final diagnosis of in situ breast 
cancer; a final diagnosis of invasive breast cancer; and a final diagnosis of either in situ or 
invasive breast cancer. We adjusted all models for age, race and ethnicity, and all other 
symptoms.
RESULTS
We abstracted the medical records of 2,961 women (n) receiving a mammogram in the 
NBCCEDP, representing 311,582 women (N) in the national MDE data after the appropriate 
sampling weights were applied. Table 1 shows the characteristics of the study population by 
whether or not they reported any breast symptoms. The majority of our sample was 50 to 
59years of age at the time of their breast cancer examination, and the majority (43.2%) was 
white. Women reporting at least 1breast symptom tended to be younger (p < 0.0001), were 
more likely to be white, non-Hispanic (54.2% vs 41.9%, p < 0.0001), and were more likely 
to report having had a previous mammogram (87.5% vs 85.2%, p < 0.0001) than those with 
no breast symptoms. Table 2 shows the breast exam results and final cancer diagnosis by 
self-report of breast symptoms. Women with symptoms were more likely to have received a 
CBE (93.0% vs 84.5%, p < 0.0001). Among all women receiving a CBE, women reporting 
symptoms were more likely to have an abnormal finding (30.4% vs 4.0%, p- < 0.0001) than 
those who did not report breast symptoms. Women with breast symptoms were also more 
likely to have a mammogram finding with a higher BI-RADS code than those without 
symptoms and slightly more likely to receive a final diagnosis of invasive cancer (4.3% vs 
2.4%) than those not reporting symptoms. Table 3 shows the distribution of patient 
characteristics by self-reported breast symptoms and clinical outcomes. Women with 
symptoms and significant clinical findings (either an abnormal exam results or a final 
diagnosis of cancer) were younger than women without symptoms and clinical findings. 
They were also more likely to be non-Hispanic white. Women with self-reported symptoms 
and an abnormal CBE or mammogram were less likely to have had a previous mammogram 
when compared to women without symptoms and a positive exam; however, women with 
symptoms and a final diagnosis of cancer did not appear more or less likely to have had a 
previous mammogram.
Figure 1 illustrates the distribution of the number of symptoms reported by women. Most 
women (89.7%) did not report a symptom at or before the time of their mammogram. 
Among the 10.3% of women who reported at least one breast symptom, 80.2% reported a 
single symptom, 17.8% reported two symptoms, 1.8% reported three, and 0.2% reported 
four. Table 4 shows the frequency of each symptom among women reporting at least one. 
The most commonly reported symptoms were pain or tenderness (49.3%) or breast lump 
(31.7%). An additional 24.1% of symptoms were reported as other or unspecified in the 
medical chart. Less common symptoms were thickening or fibrocystic changes (9.0%), 
nipple discharge (4.4%), and inflammation or changes to the skin/nipple (1.8%).
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Table 5 provides the modeling results for abnormal CBEs or mammograms or a final 
diagnosis of breast cancer by symptoms compared to women without symptoms. All 
symptoms, except for thickening or fibrocystic changes were significantly associated with 
an abnormal CBE. A reported breast lump (aOR: 3.9; 95% CI: 2.0 – 7.4) and inflammation 
or changes to the skin/nipple (aOR: 7.3; 95% CI: 1.7 – 30.8) were associated with an 
increased odds of an abnormal mammogram. Compared to women with no symptoms, 
women with a self-reported breast lump (aOR: 5.9; 95% CI: 2.3 – 14.8), or other or 
unspecified symptoms (aOR: 2.7; 95% CI: 1.1 – 6.6) had an increased odds of in situ breast 
cancer. For invasive breast cancer, women who reported a lump (aOR: 13.7; 95% CI: 7.8 – 
24.1), inflammation or changes to the skin/nipple (aOR: 27.8; 95% CI: 8.7 – 88.8), or other 
or unspecified symptoms (aOR: 3.4; 95% CI: 2.1 – 7.5) had an increased odds compared to 
those without symptoms.
DISCUSSION
About 10% of women in the NBCCEDP had an indication in their medical chart that they 
reported one or more breast symptoms at the time of receiving services. Of these, 2.0% had 
a final diagnosis of breast cancer, compared to only 0.4% of women without symptoms. 
Despite the low prevalence of cancer among women who report breast symptoms, these 
complaints are relatively frequent and their presence can elicit anxiety from both patient and 
provider (7, 16).
In our study, a final diagnosis of either in situ or invasive breast cancer was associated with 
self-reported breast lump, inflammation or changes in the skin/nipple, and other or 
unspecified breast symptoms. While it is important to know which symptoms carry the 
highest breast cancer risk, these symptoms can also be a result of benign processes. Breast 
lumps may be caused by fibroadenomas, cysts or dense breast tissue (6). Although 
inflammatory breast cancer may present with erythema, swelling and/or dimpling of the skin 
(17), breast inflammation is most often caused by infection (6). Differentials for nipple 
discharge include prolactin abnormalities, side effects from medications, and intraductal 
papilloma (6). While generalized breast pain is not associated with malignancy, pain that is 
unilateral, localized and intense may be associated with cancer (18). Guidelines for 
evaluating and treating breast disorders are available from the National Comprehensive 
Cancer Network (19). Additionally, a woman’s personal or family history of breast cancer 
and/or abnormalities may help to frame the level of suspicion when she presents with a 
breast symptom (20).
The associations we observed between certain breast symptoms and a final diagnosis of 
cancer are consistent with previous studies though the prevalence of symptoms in our study 
are markedly higher due to eligibility criteria for enrolling in the NBCCEDP which allows 
entrance simply on the basis of symptoms. In a Dutch study of family physician offices, 
overall breast symptoms were reported in about 3% of all visits by female patients and 
breast pain and breast mass were the most common breast-related complaints (16). Among 
the women complaining of breast symptoms, 3.2% had breast cancer diagnosed. Breast mass 
had a markedly elevated positive likelihood ratio for breast cancer (15.04; 95% CI, 11.74–
19.28). In another large study of postmenopausal women in an integrated health system in 
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Western Washington, researchers found that women reporting a lump had an increased odds 
of breast cancer compared with asymptomatic women (diagnostic exam: 2.8 [2.3–3.4], and 
screening exam: 3.6, 2.6–5.0). However, in this study, no other symptoms were associated 
with breast cancer after controlling for a reported lump (7). A recent study of Finland’s 
national breast cancer screening program found that breast lump or retraction reported by the 
woman or discovered upon clinical examination was associated with a diagnosis of cancer 
(OR: 6.5; 95% CI: 5.9 – 7.1 and OR: 2.2; 95% CI: 1.9 – 2.5, respectively) (21). Similarly, an 
examination of data collected from the National Cancer Control Programme in Ireland found 
that the presence of a lump (aOR: 5.6; 95% CI: 4.2 – 7.6), nipple change (aOR: 2.8; 95% CI: 
1.7 – 4.6), or nipple discharge (aOR: 2.1; 95% CI: 1.1 – 4.0) among women visiting special 
symptomatic breast units was associated with cancer (22).
This is the only project to date that examines the frequency, types, and cancer outcomes of 
breast symptoms reported in the NBCCEDP; however, it is subject to a number of 
limitations. We could only capture symptoms that were recorded in the medical chart. 
Although we employed highly trained medical record abstractors and a certified tumor 
registrar for this project, the information contained in the medical record may not have been 
complete or clear. Second, these data are older, coming from women who obtained 
NBCCEDP services between 1996 through 2004. Regardless, it is unlikely that breast 
symptom frequency or outcomes have changed since that time, though patterns in care or 
medical record documentation may have. Third, although we reviewed a large sample of 
records, the sample size was not sufficient to examine all potential associations of interest. 
Additional studies may be necessary to examine the outcome of women with some of the 
less frequently reported breast symptoms. Last, the results from this study are specific only 
to the NBCCEDP, though it provides useful information on general patterns of breast cancer 
diagnosis for both women undergoing screening and follow-up of symptoms. The 
association of breast symptoms with younger age is likely due to the patient eligibility 
criteria. The NBCCEDP allows women less than 40 years of age to be enrolled if they 
present with breast symptoms or an abnormal CBE (often found at the same time as a 
cervical cancer screening exam). The NBCCEDP’s priority population for breast cancer 
screening is women 50 years of age and older; thus, it is more likely that women enrolled 
under 50 years presented with breast symptoms in our study. Among women presenting with 
symptoms, those who are low-income with little or no health insurance are often referred to 
the NBCCEDP specifically for diagnostic services. Therefore, our study likely has a higher 
proportion of women with symptoms than would be expected in a traditional screening 
program. Furthermore, these data are unable to discern the intent of the clinician for the 
initial mammogram. Our finding that over 60% of women with symptoms did not receive 
diagnostic follow-up may be misleading as many of these women likely received a 
diagnostic mammogram that would have included more views than a screening 
mammogram and may be the only necessary follow-up. Additionally, women with 
symptoms may have been more likely to have her initial mammogram coded as assessment 
incomplete by the radiologist to prompt additional mammographic views not routinely 
included in a screening exam.
In conclusion, our data show that women in the NBCCEDP who present with a lump or 
inflammation or changes to the skin/nipple have a substantially increased risk of an 
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abnormal result on diagnostic exam and a final diagnosis of breast cancer; however, women 
who reported pain or tenderness did not have an increased cancer risk. Our findings offer 
researchers, clinicians, and patients, particularly those associated with the NBCCEDP, fresh 
understanding of the risk of breast cancer associated with breast symptoms. The NBCCEDP 
may consider more evaluation of outcomes for the potential development of guidelines or 
best practices specific for women who report breast symptoms. For example, there is some 
evidence that the sensitivity and specificity of ultrasound is greater than mammography in 
patients with breast symptoms for the detection of cancer, especially in younger women 
(23). More granular NBCCEDP monitoring tools, or the development of clinical prediction 
rules (24) may also be possible to encourage providers to deliver appropriate and timely 
follow-up for certain women with breast symptoms who may be at higher risk for cancer 
(24). Our results, along with evidence-based guidelines, can aid clinicians in the evaluation 
and diagnosis of many breast concerns.
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Distribution of the number of symptoms reported by women who received a mammogram in 
the NBCCEDP
NBCCEDP=National Breast and Cervical Cancer Early Detection Program
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Total 311,582 (100) 279,575 (100) 32,007 (100)
Age, years
<0.0001
  30–39 456 (0.2) 274 (0.1) 182 (0.6)
  40–49 59,053 (19.0) 47,844 (17.1) 11,209 (35.0)
  50–59 159,949 (51.3) 145,603 (52.1) 14,345 (44.8)
  60–69 73,372 (23.6) 67,742 (24.2) 5,630 (17.6)
  70+ 18,752 (6.0) 18,112 (6.5) 641 (2.0)
Race/Ethnicity
<0.0001
  White, non-Hispanic 134,593 (43.2) 117240 (41.9) 17353 (54.2)
  Black, non-Hispanic 58,628 (18.8) 53211 (19.0) 5417 (16.9)
  Other, non-Hispanic 22,921 (7.4) 20008 (7.2) 2912 (9.1)
  Hispanic 95,440 (30.6) 89116 (31.9) 6325 (19.8)
Previous mammogram
<0.0001  No 45,530 (14.6) 41521 (14.9) 4009 (12.5)
  Yes 266,052 (85.4) 238054 (85.2) 27998 (87.5)
    Time since last, years
<0.0001
      < 1 1,612 (0.6) 922 (0.4) 691 (2.5)
      1 to < 2 12,637 (4.8) 10552 (4.4) 2085 (7.5)
      2 to <3 101,064 (38.0) 92189 (38.7) 8874 (31.7)
      3 to < 5 65,287 (24.5) 59148 (24.9) 6139 (21.9)
      ≥ 5 79,742 (30.0) 70666 (29.7) 9076 (32.4)
      Unknown 5,710 (2.2) 4577 (1.9) 1133 (4.1)
1
Percentages may not add to 100% due to rounding
2
Pearson chi-square test of independence
NBCCEDP=National Breast and Cervical Cancer Early Detection Program; n = raw sample; N = weighted sample
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Total 311,582 (100) 279,575 (100) 32,007 (100)
Received a CBE
<0.0001  No 45,622 (14.6) 43,378 (15.5) 224 (7.0)
  Yes 265,960 (85.4) 236,197 (84.5) 29,736 (93.0)
    CBE results
<0.0001
      Normal 242,072 (91.0) 222,785 (94.3) 19,287 (64.8)
      Abnormal 18,453 (6.9) 9,408 (4.0) 9,045 (30.4)
      Unknown 5,435 (2.0) 4,004 (1.7) 1,431 (4.8)
Mammogram results
<0.0001
  Negative 178,325 (57.2) 160,878 (57.5) 17,447 (54.5)
  Benign 88,384 (28.4) 80,458 (28.8) 7,925 (24.8)
  Probably benign 12,837 (4.1) 10,652 (3.8) 2,186 (6.8)
  Suspicious abnormality 3,178 (1.0) 2,615 (0.9) 563 (1.8)
  Suggestive of malignancy 883 (0.3) 627 (0.2) 256 (0.8)
  Assessment incomplete 27,975 (9.0) 24,345 (8.7) 3,630 (11.3)
Received diagnostic follow-up
<0.0001  No 261,116 (83.8) 241,660 (86.4) 19,456 (60.8)
  Yes 50,466 (16.2) 37,915 (13.6) 12,551 (39.2)
    Final diagnosis
<0.0001
      No cancer 43,866 (86.9) 33,293 (87.8) 10,572 (84.2)
      In situ 429 (0.9) 317 (0.8) 112 (0.9)
      Invasive 1,438 (2.9) 903 (2.4) 535 (4.3)
      Unknown 4,733 (9.4) 3,402 (9.0) 1,332 (10.6)
1
Percentages may not add to 100% due to rounding
2
Pearson chi-square test of independence
NBCCEDP=National Breast and Cervical Cancer Early Detection Program; CBE=clinical breast exam; n = raw sample; N = weighted sample
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Table 4
Frequency of reported breast symptoms among women reporting at least one symptom
Symptom N (%1)
At least one symptom 32,007 (100)
  Lump 10,137 (31.7)
  Pain or tenderness 15,766 (49.3)
    Pain 7,318 (22.9)
    Tenderness 9,017 (28.2)
  Thickening or fibrocystic changes 2,877 (9.0)
    Thickening 505 (1.6)
    Fibrocystic changes 1,722 (5.4)
    Nodules 650 (2.0)
  Inflammation or changes to the skin/nipple 581 (1.8)
    Change in size or shape 193 (0.6)
  Skin dimpling or skin/nipple retraction 208 (0.7)
    Redness or inflammation of the skin 186 (0.6)
  Nipple discharge 1,419 (4.4)
  Other or unspecified 7,707 (24.1)
    Other 2,422 (7.6)
    Unspecified 5,284 (16.5)
1
Percentages do not add to 100% because women could report more than one symptom.
N = weighted sample
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